S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer

Hematology / Oncology @Point of Care Podcasts

English - December 29, 2023 18:00 - 26 minutes - 36.1 MB
Medicine Health & Fitness checkpointinhibitors cmece endometrialcancer immunotherapy Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: S19:E2 – Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer

Our faculty continue their discussion about clinical trials of HER3-directed therapies with a look at treatment-related adverse events and how to manage them.

Visit www.morningcommutepodcast.com/HER3Agnostic3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.